Brachytherapy in the therapy of prostate cancer - an interesting choice.

Publisher: Termedia Country of Publication: Poland NLM ID: 101233223 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1428-2526 (Print) Linking ISSN: 14282526 NLM ISO Abbreviation: Contemp Oncol (Pozn) Subsets: PubMed not MEDLINE

Original Publication: Poznań : Termedia

Brachytherapy is a curative alternative to radical prostatectomy or external beam radiation [i.e. 3D conformal external beam radiation therapy (CRT), intensity-modulated radiation therapy (IMRT)] with comparable long-term survival and biochemical control and the most favorable toxicity. HDR brachytherapy (HDR-BT) in treatment of prostate cancer is most frequently used together with external beam radiation therapy (EBRT) as a boost (increasing the treatment dose precisely to the tumor). In the early stages of the disease (low, sometimes intermediate risk group), HDR-BT is more often used as monotherapy. There are no significant differences in treatment results (overall survival rate - OS, local recurrence rate - LC) between radical prostatectomy, EBRT and HDR-BT. Low-dose-rate brachytherapy (LDR-BT) is a radiation method that has been known for several years in treatment of localized prostate cancer. The LDR-BT is applied as a monotherapy and also used along with EBRT as a boost. It is used as a sole radical treatment modality, but not as a palliative treatment. The use of brachytherapy as monotherapy in treatment of prostate cancer enables many patients to keep their sexual functions in order and causes a lower rate of urinary incontinence. Due to progress in medical and technical knowledge in brachytherapy ("real-time" computer planning systems, new radioisotopes and remote afterloading systems), it has been possible to make treatment time significantly shorter in comparison with other methods. This also enables better protection of healthy organs in the pelvis. The aim of this publication is to describe both brachytherapy methods.

Ann Oncol. 2010 May;21 Suppl 5:v129-33. (PMID: 20555062)
J Contemp Brachytherapy. 2011 Sep;3(3):115-20. (PMID: 23346119)
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):376-81. (PMID: 20864269)
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):565-9. (PMID: 9112454)
J Clin Oncol. 2011 Feb 1;29(4):362-8. (PMID: 21149658)
J Contemp Brachytherapy. 2011 Sep;3(3):125-30. (PMID: 23346121)
J Contemp Brachytherapy. 2011 Sep;3(3):121-4. (PMID: 23346120)
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):675-81. (PMID: 11020563)
J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. (PMID: 20141676)
Pol J Pathol. 2013 Apr;64(1):33-8. (PMID: 23625598)
J Contemp Brachytherapy. 2009 Oct;1(3):137-144. (PMID: 27807455)
World J Urol. 2006 Aug;24(3):289-95. (PMID: 16645877)
Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99. (PMID: 10386635)
BJU Int. 2005 Jul;96(1):43-7. (PMID: 15963118)
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):441-6. (PMID: 18249501)
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90. (PMID: 11777625)
Crit Rev Oncol Hematol. 2005 Dec;56(3):379-96. (PMID: 16310371)
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34. (PMID: 15752881)
J Contemp Brachytherapy. 2011 Mar;3(1):18-22. (PMID: 27877196)
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):944-52. (PMID: 14575824)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Radiother Oncol. 2000 Dec;57(3):289-96. (PMID: 11104888)
J Contemp Brachytherapy. 2012 Sep;4(3):141-5. (PMID: 23346143)
J Contemp Brachytherapy. 2011 Mar 31;3(1):26-31. (PMID: 23606866)
Radiother Oncol. 2005 Feb;74(2):137-48. (PMID: 15734201)
J Contemp Brachytherapy. 2011 Dec;3(4):183-7. (PMID: 23346126)
Radiother Oncol. 2008 Jan;86(1):114-9. (PMID: 18054101)
Pol J Pathol. 2012 Dec;63(4):272-7. (PMID: 23359198)
J Contemp Brachytherapy. 2012 Jun;4(2):69-74. (PMID: 23349647)
CA Cancer J Clin. 1995 May-Jun;45(3):165-78. (PMID: 7743420)
J Clin Oncol. 2000 Mar;18(6):1164-72. (PMID: 10715284)
Am J Clin Oncol. 2010 Oct;33(5):481-8. (PMID: 19952715)
J Contemp Brachytherapy. 2009 Mar;1(1):11-17. (PMID: 27799948)
Strahlenther Onkol. 2004 Apr;180(4):225-32. (PMID: 15057433)
J Contemp Brachytherapy. 2013 Jun;5(2):89-92. (PMID: 23878553)
J Clin Oncol. 2003 Nov 1;21(21):3979-86. (PMID: 14581420)
J Urol. 2002 Jun;167(6):2443-7. (PMID: 11992054)
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):469-75. (PMID: 20646858)
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):444-52. (PMID: 11872291)
J Contemp Brachytherapy. 2012 Jun;4(2):116-20. (PMID: 23349655)
J Contemp Brachytherapy. 2010 Sep;2(3):98-106. (PMID: 27853470)
J Contemp Brachytherapy. 2009 Jun;1(2):92-96. (PMID: 27795718)
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1286-92. (PMID: 21310546)
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9. (PMID: 11163498)
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):641-9. (PMID: 21106308)
J Urol. 2007 Jun;177(6):2106-31. (PMID: 17509297)
J Contemp Brachytherapy. 2013 Mar;5(1):33-41. (PMID: 23634153)
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27. (PMID: 12023135)
J Contemp Brachytherapy. 2013 Jun;5(2):63-9. (PMID: 23878549)
Eur Urol. 2011 Jan;59(1):61-71. (PMID: 21056534)
Radiother Oncol. 2006 Jul;80(1):62-8. (PMID: 16870289)
Radiother Oncol. 2000 Dec;57(3):315-21. (PMID: 11104892)

Keywords: HDR brachytherapy; LDR brachytherapy; prostate cancer; seeds

Date Created: 20140306 Date Completed: 20140624 Latest Revision: 20211021

20250114

PMC3934024

10.5114/wo.2013.38557

24596528